Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript

ABOS heads into a November 2026 binary event after posting a Q3 2026 net loss of $25.4 million, with $78.6 million in cash expected to fund operations into early 2027.

The catalyst is topline data from the Phase 2 ALTITUDE-AD trial, which tests sabirnetug in early Alzheimer's disease and has enrolled 542 participants. Management defined clinical success as a 30% slowing of cognitive decline on the iADRS scale. It also guided to low double-digit ARIA-E safety rates, setting a second bar the data must clear.

The balance sheet adds pressure. Cash covers only a few quarters beyond the readout, so the trial result will likely shape ABOS's financing options. That is interpretation, not company guidance: a result that meets the 30% benchmark could ease funding concerns, while a miss would leave the company with limited runway.

Beyond the trial, ABOS is advancing its Enhanced Brain Delivery program toward an IND filing in mid-2027. That timeline sits past the cash runway, so the program's progress depends on what happens at the November readout.